Company Description
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States.
Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis.
The company has a research collaboration and license agreement with Eli Lilly and Company; AbbVie Inc.; and partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.
| Country | Canada |
| Founded | 2012 |
| IPO Date | Dec 11, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 596 |
| CEO | Carl Hansen |
Contact Details
Address: 150 W 4th Avenue Vancouver, BC V5Y 1G6 Canada | |
| Phone | 604 559 9005 |
| Website | abcellera.com |
Stock Details
| Ticker Symbol | ABCL |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $20.00 |
| CIK Code | 0001703057 |
| CUSIP Number | 00288U106 |
| ISIN Number | CA00288U1066 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Andrew Knowles M.Sc. | Vice President of Operations |
| Martin Hogan M.Sc. | Senior Director of Strategic Finance and IR |
| Tiffany Chiu B.Sc., Ph.D. | Vice President of Communications |
| Caitlin Webster CIPD, M.Sc. | Director of Talent Development |
| Murray McCutcheon Ph.D. | Senior Vice President of Partnering |
| Adam Clarke M.A.I.C.D., Ph.D. | Senior Vice President of Discovery |
| Paul Colussi Ph.D. | Site Head and Vice President of Australia |
| Janna Bednenko Ph.D. | Head of Protein Expression and Genetics |
| Janet Teasdale CEC, Ed.D. | Senior Vice President of Team Development |
| Andy Clark | Head of Digital Quality Assurance |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 24, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Feb 24, 2026 | 10-K | Annual Report |
| Feb 24, 2026 | 8-K | Current Report |
| Jan 14, 2026 | 8-K | Current Report |
| Dec 18, 2025 | 8-K | Current Report |
| Nov 28, 2025 | 8-K | Current Report |
| Nov 12, 2025 | 8-K | Current Report |
| Nov 6, 2025 | 10-Q | Quarterly Report |
| Nov 6, 2025 | 8-K | Current Report |
| Sep 10, 2025 | 8-K | Current Report |